Showing 6341-6350 of 7113 results for "".
- Cynosure's SculpSure Cleared for Back, Inner and Outer Thighshttps://practicaldermatology.com/news/cynosures-sculpsure-cleared-for-back-inner-and-outer-thighs/2458155/The U.S. Food and Drug Administration (FDA) granted an expanded clearance for Cynosure's SculpSure to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen an
- FDA Cracks Down on Sonar For Distributing Unapproved Derm Drugshttps://practicaldermatology.com/news/fda-cracks-down-on-sonar-for-distributing-unapproved-derm-drugs/2458153/U.S. District Judge Kathleen M. Williams for the Southern District of Florida entered a consent decree of permanent injunction between the United States and Stratus Pharmaceuticals Inc. of Miami, Florida, Sonar Products Inc. of Carlstadt, New Jersey an
- Leo Pharma Vet Named New COO for DermaRitehttps://practicaldermatology.com/news/leo-pharma-vet-named-new-coo-for-dermarite/2458157/Barbara J. Osborne is DermaRite Industries’s new Chief Commercial Officer. In her role, Ms. Osborne will be responsible for driving the company's sales and commercialization efforts. She recently served as the U.S. Division President
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- HED Research Fuels Understanding of Male Pattern Baldnesshttps://practicaldermatology.com/news/hed-research-fuels-understanding-of-male-pattern-baldness/2458162/The origins of hypohidrotic ectodermal dysplasia (HED) may help researchers get a better handle on the genetic underpinnings of common hair disorders. The findings appear in Nature Communications. About one in 5,000 to 10,000 people are thought to have HED, although this
- Murad Adds Two New Blemish-busting Products for Acne Awareness Monthhttps://practicaldermatology.com/news/murad-adds-two-new-products-for-acne-awareness-month/2458161/June is acne awareness month, and Murad is rolling out two anti-acne new products to help patients say goodbye to blemishes. The new Pore Extractor Pomegranate Mask ($38 from Murad.com) features volcanic clay, pomegranate extract and lactic aci
- Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studieshttps://practicaldermatology.com/news/tildrakizumab-performs-well-in-two-phase-3-psoriasis-studies/2458164/Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients
- Game Change: New Handheld Tissue Scanner Can See Below Surface of Skin in Psoriasishttps://practicaldermatology.com/news/game-change-new-handheld-tissue-scanner-looks-below-surface-of-skin-in-psoriasis/2458166/A new handheld tissue scanner allows dermatologists to look below the surface of skin in psoriasis patients and can provide clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure. A team of r
- Sensus Healthcare Wins Technology Award from Greater Miami Chamber of Commercehttps://practicaldermatology.com/news/sensus-healthcare-wins-technology-award-from-greater-miami-chamber-of-commerce/2458174/Sensus Healthcare, Inc. was awarded the 2017 Technology Leader of the Year for the Disruptive Technology by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the company’s proprietary,
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The